ProCE Banner Activity

Evolution of the HDV Treatment Paradigm

Clinical Thought
Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies

Released: August 02, 2022

Expiration: August 01, 2023

Share

Faculty

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD: consultant/advisor/speaker: Aligos, Antios, Assembly, Enanta, Gilead Sciences, Janssen; researcher: Bristol Myers Squibb, Eiger, Gilead Sciences, Janssen, Target Registries; grant support: Altimmune.